Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
AU555093B2 - Calcium-antagonist composition - Google Patents
[go: Go Back, main page]

AU555093B2 - Calcium-antagonist composition - Google Patents

Calcium-antagonist composition

Info

Publication number
AU555093B2
AU555093B2 AU82384/82A AU8238482A AU555093B2 AU 555093 B2 AU555093 B2 AU 555093B2 AU 82384/82 A AU82384/82 A AU 82384/82A AU 8238482 A AU8238482 A AU 8238482A AU 555093 B2 AU555093 B2 AU 555093B2
Authority
AU
Australia
Prior art keywords
active compound
calcium
antagonistic
antagonist composition
sustaining dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU82384/82A
Other versions
AU8238482A (en
Inventor
Volker Buehler
Heinz Einig
Winfried Koch
Joachim Arthur Schwarz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF SE
Original Assignee
BASF SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6129505&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU555093(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by BASF SE filed Critical BASF SE
Publication of AU8238482A publication Critical patent/AU8238482A/en
Application granted granted Critical
Publication of AU555093B2 publication Critical patent/AU555093B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

1. A pharmaceutical composition which contains a calcium-antagonistic active compound, with or without additional active compounds, is intended for oral administration to produce a sustained action for continuous therapy and contains only the sustaining dose of active compound, bound to pharmaceutical auxiliaries, wherein the calcium-antagonistic active compound is Gallopamil or Verapamil and wherein, at the sustaining dose, the ratio of the constituents with rapid release of active compound to those with sustained release of active compound is from 1 : 0.6 to 1 : 6.
AU82384/82A 1981-04-07 1982-04-06 Calcium-antagonist composition Ceased AU555093B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19813113901 DE3113901A1 (en) 1981-04-07 1981-04-07 ACTIVE SUBSTANCE PREPARATION FOR ORAL APPLICATION
DE31139019 1981-04-07

Publications (2)

Publication Number Publication Date
AU8238482A AU8238482A (en) 1982-10-14
AU555093B2 true AU555093B2 (en) 1986-09-11

Family

ID=6129505

Family Applications (1)

Application Number Title Priority Date Filing Date
AU82384/82A Ceased AU555093B2 (en) 1981-04-07 1982-04-06 Calcium-antagonist composition

Country Status (17)

Country Link
EP (1) EP0063266B1 (en)
JP (1) JPS57175113A (en)
AT (1) ATE14076T1 (en)
AU (1) AU555093B2 (en)
CA (1) CA1184497A (en)
DE (2) DE3113901A1 (en)
DK (1) DK157482A (en)
ES (1) ES8307496A1 (en)
FI (1) FI821253L (en)
GR (1) GR74770B (en)
HU (1) HU186855B (en)
IE (1) IE52985B1 (en)
IL (1) IL65328A (en)
NO (1) NO157204C (en)
NZ (1) NZ200244A (en)
PT (1) PT74705B (en)
ZA (1) ZA822327B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4461759A (en) * 1983-01-03 1984-07-24 Verex Laboratories, Inc. Constant release rate solid oral dosage formulations of veropamil
US4874614A (en) * 1985-03-25 1989-10-17 Abbott Laboratories Pharmaceutical tableting method
US4863741A (en) * 1985-03-25 1989-09-05 Abbott Laboratories Tablet composition for drug combinations
LU86077A1 (en) * 1985-09-18 1987-04-02 Pharlyse Sa NEW GALENIC FORMS OF VERAPAMIL, THEIR MANUFACTURE AND THE MEDICINAL PRODUCTS CONTAINING THESE NEW GALENIC FORMS
LU86099A1 (en) * 1985-09-30 1987-04-02 Pharlyse EXTENDED RELEASE GALENIC FORMS OF VERAPAMIL, THEIR MANUFACTURE AND THE MEDICINAL PRODUCTS CONTAINING THEM
IE58401B1 (en) * 1986-06-20 1993-09-08 Elan Corp Plc Controlled absorption pharmaceutical composition
US4981871A (en) * 1987-05-15 1991-01-01 Abelson Mark B Treatment of ocular hypertension with class I calcium channel blocking agents
US4792452A (en) * 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
US5230901A (en) * 1988-03-23 1993-07-27 Knoll Ag Sustained release tablet of a mixture of alginates and polyacrylates
DE3809764A1 (en) * 1988-03-23 1989-10-05 Knoll Ag MIXTURE OF ALGINATES AND POLYACRYLATES AND THEIR USE
ES2045281T3 (en) * 1988-07-13 1994-01-16 Knoll Ag MEDICATION FORM OF DELAYED ACTION ON THE BASIS OF ALGINATES.
US5032406A (en) * 1989-02-21 1991-07-16 Norwich Eaton Pharmaceuticals, Inc. Dual-action tablet
DE3932378A1 (en) * 1989-09-28 1991-04-11 Knoll Ag SOLID MEDICAL FORM WITH A HIGH VERAPAMIL CONTENT
IT1264696B1 (en) * 1993-07-09 1996-10-04 Applied Pharma Res PHARMACEUTICAL FORMS INTENDED FOR ORAL ADMINISTRATION ABLE TO RELEASE ACTIVE SUBSTANCES AT A CONTROLLED AND DIFFERENTIATED SPEED
US5695781A (en) * 1995-03-01 1997-12-09 Hallmark Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers
US6083532A (en) 1995-03-01 2000-07-04 Duramed Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers and tablet formed therefrom

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1154810B (en) * 1961-04-01 1963-09-26 Knoll Ag Process for the preparation of basic substituted phenylacetonitriles
DE1467781A1 (en) * 1963-07-15 1968-12-05 Boehringer Sohn Ingelheim Process for the production of coated tablets with extended release of active ingredients

Also Published As

Publication number Publication date
AU8238482A (en) 1982-10-14
JPS57175113A (en) 1982-10-28
IE52985B1 (en) 1988-04-27
PT74705B (en) 1983-11-14
ES511208A0 (en) 1983-08-16
IL65328A (en) 1985-06-30
ES8307496A1 (en) 1983-08-16
GR74770B (en) 1984-07-12
EP0063266A3 (en) 1983-05-04
HU186855B (en) 1985-10-28
DE3113901A1 (en) 1982-10-28
EP0063266B1 (en) 1985-07-03
NO821084L (en) 1982-10-08
NO157204C (en) 1988-02-10
ATE14076T1 (en) 1985-07-15
CA1184497A (en) 1985-03-26
FI821253A7 (en) 1982-10-08
NZ200244A (en) 1984-08-24
DE3264519D1 (en) 1985-08-08
PT74705A (en) 1982-05-01
EP0063266A2 (en) 1982-10-27
ZA822327B (en) 1983-03-30
FI821253A0 (en) 1982-04-07
IE820812L (en) 1982-10-07
DK157482A (en) 1982-10-08
FI821253L (en) 1982-10-08
IL65328A0 (en) 1982-05-31
NO157204B (en) 1987-11-02

Similar Documents

Publication Publication Date Title
AU555093B2 (en) Calcium-antagonist composition
EP0427247A3 (en) Pharmaceutical composition with r-alpha-lipoic acid or s-alpha-lipoic acid as the active ingredient
IL80149A (en) Pharmaceutical compositions containing toluidide derivatives against graft-versus-host diseases and autoimmune diseases
TW234691B (en)
DE60022895D1 (en) PDGF-RECEPTOR-KINASE-INHIBITABLE COMPOUNDS, THE PREPARATION, CLEANING AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS
DE3566545D1 (en) 2-substituted-1,3-propylidenediphosphonate derivatives, the process for their preparation and pharmaceutical compositions containing them
DK0629400T3 (en) Idebenone-containing preparations for the treatment of Alzheimer's disease
AU563762B2 (en) S-adenosyl-l-methionine salts preparation
KR830002510A (en) Composition consisting of biologically active compound and hydroxyalkyl starch
KR890004705A (en) Antiviral agents
ATE18203T1 (en) (-)-15-DEOXYSPERGUALIN, ITS MANUFACTURE AND MEDICATIONS CONTAINING THIS ACTIVE SUBSTANCE.
ZA858742B (en) Anticoccidial compositions
ATE85218T1 (en) ORAL PHARMACEUTICAL FORM FOR THE TREATMENT OF HYPERTENSION WITH DILTIAZEM HYDROCHLORIDE ONCE DAILY.
HK8994A (en) Medicament for treatment of pregnancy-induced hypertension
WO1987003590A1 (en) Medicament for the treatment of diseases of the liver
IL87867A (en) Preparation of pharmaceutical compositions containing a 2,6-diamino-3-phenyl-azo-pyridine derivative
IE780530L (en) Anti-histamine salts and compositions
JPS54126737A (en) Antithrombotic agent
ATE15041T1 (en) ANTI-PAIN RELIEF, ANTI-INFLAMMATORY AND ANTIPYREXIC COMPOUND, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
FR2567755B1 (en) NEW ANTI-TUMOR DRUG CONTAINING TRIACETOXY-1,8,9 ANTHRACENE AS ACTIVE INGREDIENT